Motamed C, Kirov K, Lieutaud T, Duvaldestin P
Department of Anesthesia, Hôpital Henri-Mondor, Université Paris XII, Créteil, France.
Anesth Analg. 2000 Sep;91(3):732-5. doi: 10.1097/00000539-200009000-00044.
The neuromuscular blocking effects of mivacurium are greatly enhanced when mivacurium is preceded by a subparalyzing dose of pancuronium. The mechanism of this potentiation has not been elucidated. This study investigated the effects of the anticholinesterase activity of a small dose of pancuronium on the neuromuscular blocking effects of mivacurium. Forty patients were enrolled in the study. The neuromuscular effects of 7.5 and 15 microg/kg pancuronium, followed by 50 and 100 microg/kg mivacurium, were assessed in Groups PM1 and PM2 (n = 20), respectively. The neuromuscular effects of 65 and 130 microg/kg mivacurium were assessed in Groups M1 and M2 (n = 20), respectively. One arm was excluded from circulation with a tourniquet, which was inflated before the injection of pancuronium and deflated 3 min after the injection of mivacurium. The plasma cholinesterase activity was measured before induction for all patients and 3 min after the injection of pancuronium for Groups PM1 and PM2. The plasma cholinesterase activity was decreased by 16% and 33% after pancuronium administration in Groups PM1 and PM2, respectively. In the nonexcluded arm, pancuronium significantly potentiated the effects of mivacurium. In the excluded arm, no significant block was detected for Groups M1 and M2, whereas the maximal degree of neuromuscular block was 79% and 100% for Groups PM1 and PM2, respectively. Using the isolated-arm technique, we suggest that pancuronium potentiation of the neuromuscular blocking effects of mivacurium is more likely attributable to an increase in the effective plasma concentration of mivacurium than to occupancy of postsynaptic acetylcholine receptors.
Using the isolated-arm technique, we suggest that pancuronium potentiation of the neuromuscular blocking effects of mivacurium is more likely attributable to an increase in the effective plasma concentration of mivacurium than to occupancy of postsynaptic acetylcholine receptors.
在米库氯铵之前给予低于麻痹剂量的潘库溴铵时,米库氯铵的神经肌肉阻滞作用会大大增强。这种增强作用的机制尚未阐明。本研究调查了小剂量潘库溴铵的抗胆碱酯酶活性对米库氯铵神经肌肉阻滞作用的影响。40例患者纳入本研究。分别在PM1组和PM2组(n = 20)中评估了7.5和15μg/kg潘库溴铵后给予50和100μg/kg米库氯铵的神经肌肉效应。分别在M1组和M2组(n = 20)中评估了65和130μg/kg米库氯铵的神经肌肉效应。用止血带阻断一侧手臂的血液循环,在注射潘库溴铵前充气,在注射米库氯铵后3分钟放气。测量所有患者诱导前以及PM1组和PM2组注射潘库溴铵后3分钟的血浆胆碱酯酶活性。PM1组和PM2组注射潘库溴铵后血浆胆碱酯酶活性分别降低了16%和33%。在未阻断血液循环的手臂中,潘库溴铵显著增强了米库氯铵的作用。在阻断血液循环的手臂中,M1组和M2组未检测到明显阻滞,而PM1组和PM2组神经肌肉阻滞的最大程度分别为79%和100%。使用单臂技术,我们认为潘库溴铵增强米库氯铵的神经肌肉阻滞作用更可能是由于米库氯铵有效血浆浓度的增加,而不是由于占据突触后乙酰胆碱受体。
使用单臂技术,我们认为潘库溴铵增强米库氯铵的神经肌肉阻滞作用更可能是由于米库氯铵有效血浆浓度的增加,而不是由于占据突触后乙酰胆碱受体。